US SB73 | 2019-2020 | 116th Congress

Status

Spectrum: Strong Partisan Bill (Democrat 21-2)
Status: Introduced on January 10 2019 - 25% progression, died in committee
Action: 2019-01-10 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Prohibits tax deductions for expenses relating to direct-to-consumer advertising of prescription drugs. "Direct-to-consumer advertising" is any dissemination, by or on behalf of a sponsor of a prescription drug product, of an advertisement that is (1) in regard to the drug product, and (2) primarily targeted to the general public.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

End Taxpayer Subsidies for Drug Ads Act

Sponsors


History

DateChamberAction
2019-01-10SenateRead twice and referred to the Committee on Finance.

Same As/Similar To

SB1801 (Related) 2019-06-12 - Read twice and referred to the Committee on Finance.
HB8399 (Same As) 2020-09-25 - Referred to the House Committee on Ways and Means.

Subjects


US Congress State Sources


Bill Comments

feedback